Revance Therapeutics Inc. (NASDAQ:RVNC) has a beta of 1.29. The stock’s Relative Strength Index (RSI) is 61.13, with weekly volatility at 3.88% and ATR at 1.18. The RVNC stock’s 52-week price range has touched low of $20.35 and a $34.62 high. Its shares traded lower over the last trading session, losing -0.17% on 05/27/21. The shares fell to a low of $29.14 before closing at $29.67. Intraday shares traded counted 0.73 million, which was -73.01% lower than its 30-day average trading volume of 419.29K. RVNC’s previous close was $29.72 while the outstanding shares total 66.64M.
Investors have identified the Biotechnology company Revance Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.13 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Revance Therapeutics Inc. (RVNC) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 406.43 million total, with 50.84 million as their total liabilities.
RVNC were able to record -78.79 million as free cash flow during the 08/05/2021 quarter of the year, this saw their quarterly net cash flow reduce by -84.13 million. In cash movements, the company had a total of -74.75 million as operating cash flow.
Potential earnings growth for Revance Therapeutics Inc. (RVNC)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/05/2021 quarter of the year, Revance Therapeutics Inc. recorded a total of 13.3 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 99.56% coming in sequential stages and their sales for the 08/05/2021 quarter increasing by 16.29%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 4.22 million trying to sell their products during the last quarter, with the result yielding a gross income of 9.08 million. This allows shareholders to hold on to 66.64M with the recently reported earning now reading -1.08 cents per share. This is a figure that compared to analyst’s prediction for their 08/05/2021 (-1.08 cents a share).
Having a look at the company’s valuation, the company is expected to record -2.97 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on RVNC sounds very interesting.
Is the stock of RVNC attractive?
In related news, President, Innovation & Tech, Rankin Aubrey sold 2 shares of the company’s stock in a transaction that recorded on Apr 05. The sale was performed at an average price of 28.28, for a total value of 57. As the sale deal closes, the President, Innovation & Tech, Rankin Aubrey now sold 33,119 shares of the company’s stock, valued at 842,216. Also, President, Innovation & Tech, Rankin Aubrey sold 33,119 shares of the company’s stock in a deal that was recorded on Feb 01. The shares were price at an average price of 25.95 per share, with a total market value of 859,438. Following this completion of acquisition, the President, Innovation & Tech, Rankin Aubrey now holds 33,119 shares of the company’s stock, valued at 921,212. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.80%.
10 out of 11 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Revance Therapeutics Inc.. 0 analysts has assigned a Sell rating on the RVNC stock. The 12-month mean consensus price target for the company’s shares has been set at $38.50.